Youre a good candidate for this treatment if you: Patients with a personal or family history of medullary thyroid carcinoma or MEN2, active pancreatitis, or allergy to the medication are generally NOT candidates
These are generally mild and tend to lessen over time, especially when the dose is adjusted gradually
In Phase 2 clinical trials (NEJM, 2023), retatrutide was administered as a once-weekly subcutaneous injection , following a structured dose-escalation schedule
Later on, in the addiction cycle, relapse drinking after alcohol withdrawal is an important aspect of AUD, and this can be modeled using the alcohol deprivation test in rats (Sanchis-Segura and Spanagel, 2006)
The strategies that worked for you before might not be as effective anymore, and thats completely normal
doi: 10.1080/13880209.2021.1948065 106 LipinskiCALombardoFDominyBWFeeneyPJ